irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
9 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma
HR070803-307, NCT06217042: HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting
3
524
RoW
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, gemcitabine; capecitabine
Fudan University
Pancreatic Cancer
03/27
07/28
NCT05751850: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting
3
778
RoW
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
Jiangsu HengRui Medicine Co., Ltd.
First-line Treatment of Advanced Pancreatic Cancer
12/24
12/25
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Recruiting
2/3
606
RoW
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
12/25
12/26
NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Recruiting
2
30
RoW
HR070803
Jiangsu HengRui Medicine Co., Ltd.
Advanced Esophageal Cancer
01/23
03/23
NCT06383078: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting
2
120
NA
HR070803, Irinotecan Liposome, Oxaliplatin, L-OHP, Tegafur, S-1, Folinic acid, LV, 5-Fluorouracil, 5-FU
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety
03/27
12/27
NCT06827717: Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Not yet recruiting
2
29
NA
irinotecan liposome (II) + temozolomide + fluzoparib
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Ewing Sarcoma
02/27
02/28
ChiCTR2300078203: Single arm, exploratory, multicenter phase II clinical study of HR070803 combined with oxaliplatin, 5-fluorouracil and calcium folinate for first-line treatment of advanced pancreatic cancer

Recruiting
2
25
 
1. Oxaliplatin for injection: dosage 60mg/m2, intravenous infusion for 2 hours or root According to the clinical practice of the research center; 2. HR070803: Dose is 56.5mg/m2, intravenous infusion for 90 minutes (±30min); 3. Calcium folinate: Dose 400mg/m2, complete intravenous infusion within 30 minutes or according to clinical practice at the research center; 4. 5-fluorouracil: Dose of 2400mg/m2 (infusion for 46-48 hours or root). According to clinical practice at the research center, intravenous infusion. Corresponding preventive medication can be selected according to clinical needs. Every 14 days is a treatment cycle, and all drugs are administered on the first day.
Peking University Cancer Hospital; Peking University Cancer Hospital, Self raised funds
pancreatic cancer
 
 
ChiCTR2400079899: A randomized, open, parallel-controlled, multi-center phase III clinical study of HR070803 combined with oxaliplatin, 5-fluorouracil, and leucovorin versus gemcitabine combined with capecitabine for postoperative adjuvant treatment of pancreatic cancer.

Recruiting
1
524
 
HR070803+Oxaliplantin+5-FU/LV; Gemcitabine+Capecitabine
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, self-funded
pancreatic cancer
 
 
ChiCTR2300075966: Second-line treatment of metastatic colorectal cancer with HR070803 in combination with 5-FU/LV and BP102

Not yet recruiting
N/A
89
 
HR0708035, FU/LV and BP102
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, funding
colorectal cancer
 
 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
irinotecan hydrochloride liposome injection (HR070803) / Jiangsu Hengrui Pharma
HR070803-307, NCT06217042: HR070803 in Combination With Oxaliplatin, 5-fluorouracil/LV Versus GX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting
3
524
RoW
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, gemcitabine; capecitabine
Fudan University
Pancreatic Cancer
03/27
07/28
NCT05751850: HR070803 in Combination With Oxaliplatin, 5-FU/LV Versus AG for First-line Treatment of Advanced Pancreatic Cancer

Recruiting
3
778
RoW
HR070803; Oxaliplatin; 5Fluorouracil; Calcium folinate, nab-paclitaxel; gemcitabine
Jiangsu HengRui Medicine Co., Ltd.
First-line Treatment of Advanced Pancreatic Cancer
12/24
12/25
NCT05945901: A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer

Recruiting
2/3
606
RoW
HR070803 plus oxaliplatin, 5-FU/LV, bevacizumab, HR070803 simulator plus oxaliplatin, 5-FU/LV, bevacizumab
Jiangsu HengRui Medicine Co., Ltd.
Colorectal Cancer
12/25
12/26
NCT05425472: A Phase II Study of HR070803 in the Treatment of Advanced Esophageal Cancer

Recruiting
2
30
RoW
HR070803
Jiangsu HengRui Medicine Co., Ltd.
Advanced Esophageal Cancer
01/23
03/23
NCT06383078: HR070803 in Combination With Oxaliplatin, S-1 Versus NALIRIFOX as Adjuvant Therapy for Pancreatic Cancer

Not yet recruiting
2
120
NA
HR070803, Irinotecan Liposome, Oxaliplatin, L-OHP, Tegafur, S-1, Folinic acid, LV, 5-Fluorouracil, 5-FU
The First Affiliated Hospital with Nanjing Medical University
Efficacy and Safety
03/27
12/27
NCT06827717: Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

Not yet recruiting
2
29
NA
irinotecan liposome (II) + temozolomide + fluzoparib
Sun Yat-sen University, Jiangsu Hengrui Pharmaceutical Co., Ltd.
Ewing Sarcoma
02/27
02/28
ChiCTR2300078203: Single arm, exploratory, multicenter phase II clinical study of HR070803 combined with oxaliplatin, 5-fluorouracil and calcium folinate for first-line treatment of advanced pancreatic cancer

Recruiting
2
25
 
1. Oxaliplatin for injection: dosage 60mg/m2, intravenous infusion for 2 hours or root According to the clinical practice of the research center; 2. HR070803: Dose is 56.5mg/m2, intravenous infusion for 90 minutes (±30min); 3. Calcium folinate: Dose 400mg/m2, complete intravenous infusion within 30 minutes or according to clinical practice at the research center; 4. 5-fluorouracil: Dose of 2400mg/m2 (infusion for 46-48 hours or root). According to clinical practice at the research center, intravenous infusion. Corresponding preventive medication can be selected according to clinical needs. Every 14 days is a treatment cycle, and all drugs are administered on the first day.
Peking University Cancer Hospital; Peking University Cancer Hospital, Self raised funds
pancreatic cancer
 
 
ChiCTR2400079899: A randomized, open, parallel-controlled, multi-center phase III clinical study of HR070803 combined with oxaliplatin, 5-fluorouracil, and leucovorin versus gemcitabine combined with capecitabine for postoperative adjuvant treatment of pancreatic cancer.

Recruiting
1
524
 
HR070803+Oxaliplantin+5-FU/LV; Gemcitabine+Capecitabine
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, self-funded
pancreatic cancer
 
 
ChiCTR2300075966: Second-line treatment of metastatic colorectal cancer with HR070803 in combination with 5-FU/LV and BP102

Not yet recruiting
N/A
89
 
HR0708035, FU/LV and BP102
Fudan University Shanghai Cancer Center; Fudan University Shanghai Cancer Center, funding
colorectal cancer
 
 

Download Options